By analyzing existing forward-looking signals between Mink Therapeutics and Brickell, you can compare the effects of market volatilities on both companies' prices and check if they can diversify away market risk if combined in one of your portfolios. You can also utilize pair trading strategies for matching a long position in Brickell with a short position in Mink Therapeutics. Check out our
pair correlation module for more information.
Let's begin by analyzing the assets.
The concept of asset utilization usually refers to the revenue earned for every dollar of assets a company currently reports. The newest return on assets of Mink Therapeutics implies not a very effective usage of assets in March.
Out of tens of thousands of stocks, funds, and ETFs that trade on global exchanges each represent an individual company which you can analyze using comparative analysis. To determine which one of the two entities, such as Mink or Cue is a better fit for your portfolio, analyzing a few basic fundamental indicators is a good first step.
How important is Mink Therapeutics's Liquidity
Mink Therapeutics
financial leverage refers to using borrowed capital as a funding source to finance Mink Therapeutics ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Mink Therapeutics financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Mink Therapeutics' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Mink Therapeutics' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the
breakdown between Mink Therapeutics's total debt and its cash.
Correlation Between Mink and Cue Biopharma
In general, Stock analysis is a method for investors and traders to make individual buying and selling decisions. Stock correlation analysis is also essential because it can help investors realize that they may not be as diversified as they think. Risk management strategies are usually required to make sure all portfolios are properly aligned against their risk tolerance level. You can consider holding Mink Therapeutics together with similar or unrelated positions with a negative correlation. For example, you can also add Cue Biopharma to your portfolio. If Cue Biopharma is not perfectly correlated to Mink Therapeutics it will diversify some of the market risks out of the positively correlated stocks in your portfolio. However, the disadvantage of this sort of hedging is that it can potentially affect your investment returns throughout market cycles. When Mink Therapeutics, for example, performs excellent and delivers stable returns, the negatively correlated position you locked in as a hedge may drag your returns down.
Are you currently holding both Mink Therapeutics and Cue Biopharma in your portfolio? Please note if you are using this as a pair-trade strategy between Mink Therapeutics and Cue Biopharma, watch out for correlation discrepancy over time. Relying on the historical price correlations and assuming that it will not change may lead to short-term losses. Please check
pair correlation details between INKT and CUE for more information.
A Deeper Perspective On Mink Therapeutics
Cash and Equivalents Breakdown
Let me take a closer look at Mink Therapeutics cash and equivalents. In accordance with the recently published financial statements, Mink Therapeutics has 819.45
K in Cash and Equivalents. This is 99.9% lower than that of the Healthcare sector and 99.82% lower than that of the
Biotechnology industry. The cash and equivalents for all United States stocks is 99.97% higher than that of Mink Therapeutics. As for Brickell Biotech we see cash and equivalents of 21.38
M, which is 95.22% lower than that of the Biotechnology
| INKT | 819,450 | 0.17 |
| Sector | 447.12 Million | 95.27 |
| BBI | 21.38 Million | 4.56 |
Another 3 percent gain for Mink Therapeutics
Variance is down to 56.27. It may call for a possible volatility drop.
As of the 17th of March 2022, Mink Therapeutics secures the
risk adjusted performance of
(0.13), and Mean Deviation of 5.63. Mink Therapeutics
technical analysis lets you operate historical price patterns with an objective to determine a pattern that forecasts the direction of the firm's future prices. Strictly speaking, you can use this information to find out if the firm will indeed mirror its model of past prices, or the prices will eventually revert. We were able to collect data for nineteen
technical drivers for Mink Therapeutics, which can be compared to its peers in the industry. Please verify
Mink Therapeutics coefficient of variation,
treynor ratio, as well as the
relationship between the Treynor Ratio and
semi variance to decide if Mink Therapeutics is priced some-what accurately, providing market reflects its recent price of 3.1 per share. Given that Mink Therapeutics has
jensen alpha of
(0.88), we recommend you to check Mink Therapeutics's last-minute market performance to make sure the company can sustain itself at a future point.
Our Bottom Line On Mink Therapeutics
Whereas many of the other players in the biotechnology industry are either recovering or due for a correction, Mink Therapeutics may not be as strong as the others in terms of longer-term growth potentials. In closing, as of the 17th of March 2022, we believe that at this point, Mink Therapeutics is
undervalued with
average probability of distress within the next 2 years. Our primary buy-hold-sell recommendation on the firm is
Hold.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Ellen Johnson is a Member of Macroaxis Editorial Board. Ellen covers public companies in North America, focusing primarily on valuation and volatility. Six years of experience in predictive investment analytics and risk management.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of Mink Therapeutics. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com
